Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26055615
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Am+J+Cardiovasc+Drugs
2015 ; 15
(5
): 323-35
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Non-vitamin K antagonist oral anticoagulants: new choices for patient management
in atrial fibrillation
#MMPMID26055615
Saliba W
Am J Cardiovasc Drugs
2015[Oct]; 15
(5
): 323-35
PMID26055615
show ga
Atrial fibrillation (AF) is a significant problem for the aging population and
remains a major factor underlying stroke risk. Warfarin anticoagulation has been
proven effective for stroke prevention in AF, but can be difficult to manage and
requires frequent monitoring. The non-vitamin K antagonist oral anticoagulants
(NOACs) have been shown to be as effective as warfarin for stroke prevention in
nonvalvular AF (NVAF) and are associated with a reduced risk of bleeding compared
with warfarin. Dabigatran, rivaroxaban, apixaban, and edoxaban have been approved
in the USA for reducing the risk of stroke in patients with NVAF. In this
article, AF risk assessment is discussed and NOAC phase III clinical trials for
the prevention of stroke and systemic embolic events are reviewed. Further,
differences in stroke and bleeding outcomes between NOACs are highlighted, the
use of NOACs for cardioversion and special patient populations is discussed, and
management considerations for patients with AF are reviewed.